SOURCE: The Alliance for Regenerative Medicine

October 17, 2013 09:00 ET

The Alliance for Regenerative Medicine Issues Statement Regarding CIRM President Alan Trounson's Decision to Step Down

WASHINGTON, DC--(Marketwired - Oct 17, 2013) - The Alliance for Regenerative Medicine (ARM), the largest multi-stakeholder advocacy organization representing regenerative medicine, issues the following statement about the announcement of Dr. Alan Trounson's decision to step down as President of the California Institute for Regenerative Medicine (CIRM).

"We owe a huge debt of gratitude to Alan for his pivotal contributions to the field of regenerative medicine," said Morrie Ruffin, Managing Director of ARM. "His leadership as President of CIRM during a crucial phase in the growth of this sector provided a strong, forceful voice for novel strategies to create breakthrough therapies."

CIRM is a charter member of ARM and Dr. Trounson has served on the Executive Committee of the Board of Directors since 2009. ARM and CIRM work together on a number of joint initiatives to address major translational and commercial challenges in the field.

"Alan's legacy pioneering a field that will change medicine is that of a thoughtful leader, tireless advocate and a champion of important science," said Michael Werner, Executive Director of ARM. "We've enjoyed collaborating with Alan as the leader of CIRM and are committed to continue working with the organization to move these technologies to patients."

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 145 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.

Contact Information

  • Media Contact:
    Michelle Linn
    Linnden Communications
    Phone: 774-696-3803